Clinical trial
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With…
NCT00004213 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00004213 |
|---|---|
| Title | 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors |
| Official title | An Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in Cancer Patients Using a Single Daily Dose for Five Days |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | triapine |
| Start date | May 1, 1998 |
| Completion | Jan 1, 2008 |
| First posted | May 3, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: